23 Feb 2018 --- BASF is launching Hepaxa to help patients manage non-alcoholic fatty liver disease in what the corporation describes as “the first dedicated product in the US” to potentially assist tens of millions of patients with one of the most common forms of chronic liver disease. And it could begin to “turn around” non-alcoholic fatty liver disease (NAFLD) in as little as six months, according to BASF executives.
